Opportunities and Challenges in Antiparasitic Drug Discovery

  title={Opportunities and Challenges in Antiparasitic Drug Discovery},
  author={R. Pink and Alan Hudson and M. A. Mouries and Mary Margaret Bendig},
  journal={Nature Reviews Drug Discovery},
New antiparasitic drugs are urgently needed to treat and control diseases such as malaria, leishmaniasis, sleeping sickness and filariasis, which affect millions of people each year. However, because the majority of those infected live in countries in which the prospects of any financial return on investment are too low to support market-driven drug discovery and development, alternative approaches are needed. In this article, challenges and opportunities for antiparasitic drug discovery are… 
Antileishmanial Drugs: search for t SIR2 inhibitors
An overview of the main strategies for antileishmanial drug development, mainly focused on the target-based drug development approach, is given.
New chemotherapeutic strategies against malaria, leishmaniasis and trypanosomiases.
This review deals with new drugs against Plasmodium, Leishmania and Trypanosoma parasites, focusing on the molecules that are in the most advanced stage of development.
Recent Advances in the Discovery of Novel Antiprotozoal Agents
This review has compiled the latest information on the structures and pharmacological activities of newly developed organic compounds against five major protozoan diseases, giardiasis, leishmaniasis, malaria, trichomoniasis, and trypanosomiasis, with the aim of showing recent advances in the discovery of new antiprotozoal drugs.
Repurposing Drugs to Fight Hepatic Malaria Parasites
Assessment of the anti-plasmodial activity of existing drugs, with an emphasis on the obligatory and clinically silent liver stage of infection, and the current knowledge on the classes of compounds that might be therapeutically relevant against Plasmodium in the context of other communicable diseases.
Antitrypanosomal and antileishmanial activities
The search for active compounds that provide the basis for the development of new therapies capable of generating curing against T. cruzi and Leishmania spp.
Antileishmanial Drug Discovery and Development: Time to Reset the Model?
An overview of the currently used drugs, the prevailing model to develop new antileishmanial drugs and its low efficiency, and the impact of deconstruction of the drug pipeline on the high failure rate of potential drugs are presented.


Medicines for Malaria Venture new developments in antimalarials.
Antimalarial drug discovery: old and new approaches
  • P. Rosenthal
  • Biology, Medicine
    Journal of Experimental Biology
  • 2003
A number of new antimalarial therapies will likely be needed over the coming years, so it is important to pursue multiple strategies for drug discovery.
Antimalarial drug discovery: efficacy models for compound screening
Different in vitro and in vivo screens for antimalarial drug discovery are suggested and a streamlined process for evaluating new compounds on the path from drug discovery to development is recommended.
New chemotherapeutic approaches for the treatment of Chagas disease (American Trypanosomiasis)
In this review the patent literature for the period 1999 – 2002 was searched for claims of potential treatments for Chagas disease and 13 specific patents were identified and the majority of these patents dealt with inhibitors of cruzipain, a specific cysteine protease, which has been shown to be essential for the survival and growth of T. cruzi in its mammalian hosts.
Specific chemotherapy of Chagas disease: controversies and advances.
RNAi-based discovery and validation of new drug targets in filarial nematodes.
Identification of an antimalarial synthetic trioxolane drug development candidate
Here it is described how a synthetic peroxide antimalarial drug development candidate was identified in a collaborative drug discovery project.
The life and times of ivermectin — a success story
The drug arose from a unique international collaboration between the public and private sectors, which incorporated the world's first and largest drug-donation programme and involved a unique association between governments, non-governmental organizations and industry.
Antiparasitic properties of medicinal plants and other naturally occurring products.